Astellas has formulated "Corporate Strategic Plan 2021" and has positioned DX as a critical enabler there. Pharmaceutical R&D is a highly uncertain space, with a long-term required to bring a drug to market and a low probability of success. Inductive analytics based on existing data is not sufficient for DX success in corporate management; new digital technologies are needed to introduce deductive modeling into strategic decision making. I will introduce our efforts to maximize VALUE for patients by utilizing the power of analytics and modeling to all value chains, from high-level decision making, such as drug portfolio strategy, to the development and marketing of individual products, and even to the implementation of HR and organizational change.